explore -WSS

explore

author：focus 2025-09-30 20:34:45 - browse：22

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

leisure time

WSS

AI used to predict Covid

Insmed lung disease drug hits target in key Phase 3 trial

Latest bird flu infection made farmworker sicker than earlier cases

AI used to predict Covid

Heat waves linked to early deliveries, preterm births in new study

AI used to predict Covid

leisure time

explore

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Biohaven protein

State Dept. review finds Biden bears some blame for Afghanistan failures

David Sabatini, ex

Peter Hotez and the public health issue of online harassment

Heat waves linked to early deliveries, preterm births in new study

Activists slam private health insurers over coverage restrictions

Report: NIH

New air purifier tech could be key to improving indoor air quality

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

focus

Insmed lung disease drug hits target in key Phase 3 trial

Stigma and the return of syphilis

Antibiotic resistance nearly killed me, so I'm raising awareness of it

David Sabatini, ex

Insmed lung disease drug hits target in key Phase 3 trial

Stigma and the return of syphilis

hotspot

Wikipedia

knowledge

focus